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APHP, Paris, FranceRecessive dystrophic epidermolysis bullosa is a rare and severe
genetic skin disease resulting in blistering of the skin and mu-
cosa. Recessive dystrophic epidermolysis bullosa (RDEB) is
caused by a wide variety of mutations in COL7A1-encoding
type VII collagen, which is essential for dermal-epidermal
adhesion. Here we demonstrate the feasibility of ex vivo
COL7A1 editing in primary RDEB cells and in grafted
3D skin equivalents through CRISPR/Cas9-mediated homol-
ogy-directed repair. We designed five guide RNAs to correct
a RDEB causative null mutation in exon 2 (c.189delG;
p.Leu64Trpfs*40). Among the site-specific guide RNAs tested,
one showed significant cleavage activity in primary RDEB
keratinocytes and in fibroblasts when delivered as integra-
tion-deficient lentivirus. Genetic correction was detected in
transduced keratinocytes and fibroblasts by allele-specific
highly sensitive TaqMan-droplet digital PCR (ddPCR), result-
ing in 11% and 15.7% of corrected COL7A1mRNA expression,
respectively, without antibiotic selection. Grafting of geneti-
cally corrected 3D skin equivalents onto nude mice showed
up to 26% re-expression and normal localization of type VII
collagen as well as anchoring fibril formation at the dermal-
epidermal junction. Our study provides evidence that precise
genome editing in primary RDEB cells is a relevant strategy
to genetically correct COL7A1 mutations for the development
of future ex vivo clinical applications.Received 2 March 2018; accepted 22 June 2018;
https://doi.org/10.1016/j.omtn.2018.06.008.
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Dystrophic epidermolysis bullosa (DEB) is a rare and severe genetic
skin disease of children and adults, responsible for blistering of the
skin and mucosa. DEB is caused by a wide variety of mutations in
the COL7A1 gene-encoding type VII collagen.1 Type VII collagen is
the major component of anchoring fibrils (AFs), which are key
attachment structures for dermal-epidermal adhesion.2 COL7A1mu-
tations lead to defective AF formation, resulting in a loss of adhesion
between the epidermis and the dermis.3 Depending on the nature and
position of COL7A1 mutations, the disease is either dominantly or
recessively inherited,4 dominant forms (DDEB) being usually less se-554 Molecular Therapy: Nucleic Acids Vol. 12 September 2018 ª 2018
This is an open access article under the CC BY license (http://creativere than recessive forms. Generalized severe recessive DEB (RDEB)
is one of the most severe genodermatoses in children.5 Individuals
with RDEB undergo continuous wound healing and tissue repair,
often associated with significant local and systemic complications,
leading to mutilating scarring, contracture deformities, fusion of fin-
gers and toes, chronic skin inflammation, anemia, malnutrition, and a
dramatically increased risk of developing squamous cell carcinomas
at sites exposed to continuous wounding.6 No specific cure is
currently available for RDEB and proposed treatments are mainly
symptomatic.7
Recent gene-targeting studies have highlighted the potential of precise
correction of disease-causing mutations in primary cells by site-spe-
cific nucleases, such as meganucleases (MNs), zinc-finger nucleases
(ZFNs), transcription activator-like effector nucleases (TALENs), or
CRISPR/Cas9.8–11 These nucleases can induce DNA double-strand
breaks (DSBs) at specific loci and stimulate homology-directed repair
(HDR) in the presence of a Donor template.12–14
During the last 5 years, we and others could achieve gene editing
in RDEB cells using nuclease-based approaches.15–18 First, Osborn
and colleagues15 obtained up to 2% of genetic correction in RDEB pa-
tient-derived fibroblasts through TALEN-mediated HDR. Using anti-
biotic selection, corrected cells were reprogrammed into induced
pluripotent stem cells (iPSCs), and type VII collagen rescue was
demonstrated by in vivo teratoma assay. We reported up to 4% of
COL7A1 correction of two disease-causing mutations using MN-
mediated HDR in an RDEB patient-derived keratinocyte cell line
and in primary RDEB keratinocytes (RDEB-Ks) and fibroblasts
(RDEB-Fs).16 Recently, Hainzl and colleagues achieved genetic and
functional correction of a disease-causing mutation in an RDEB-KThe Authors.
vecommons.org/licenses/by/4.0/).
www.moleculartherapy.orgcell line through CRISPR/Cas9-mediated HDR using antibiotic- or
fluorescence-based selection. Rescue of C7 was demonstrated in
skin grafts composed of genetically corrected keratinocytes’ cell
line without evidence of AF formation at the dermal-epidermal
junction.18
The achievements described above represent important steps in gene
correction for RDEB through nuclease-mediated HDR. However,
several major drawbacks prevent their direct translation to the clinic.
These include the low efficiency of gene correction using sequence-
specific nucleases such as MNs or TALENS, the limited efficacy of
non-viral delivery methods to skin cells, and the use of antibiotic-
or fluorescence-based selection to enrich targeted cell populations.
These limitations need to be overcome in order to consider the use
of genetically corrected transplantable skin grafts for future clinical
applications.
In this study, we developed an ex vivo gene therapy approach based on
CRISPR/Cas9-mediated COL7A1 editing without antibiotic- or fluo-
rescence-based selection. We achieved efficient COL7A1 editing in
primary RDEB-Ks and RDEB-Fs, and we demonstrate functional
rescue of type VII collagen expression and AF formation in an
ex vivo xenograft model using gene-edited RDEB skin grafts.
RESULTS
Design of Guide RNAs Targeting Exon 2 of COL7A1
To demonstrate the feasibility of COL7A1 editing in primary RDEB
cells using the CRISPR/Cas9 approach, we designed five guide
RNAs (gRNAs) in order to correct a causative null mutation in
exon 2 seen in several RDEB subjects (c.189delG; p.Leu64Trpfs*40).
To avoid or to limit off-target events, we used gRNAs with improved
design (17- to 18-bp length instead of 20 nt).19 Five gRNAs were iden-
tified by ZiFiT Targeter 4.2 (http://zifit.partners.org) software in the
human genome (Figure 1A). Target sites of these gRNAs are located
in close distance (5–44 bp downstream or upstream) from the
mutation to be corrected (Table S1). No other sequence within the
human genome showed 100% identity to these target sites.
Activity Assessment of gRNAs Targeting Exon 2 of COL7A1
First, the selected five gRNAs (gRNA N1 to gRNA N5) were cloned
into an expression plasmid and delivered together with a plasmid
encoding for Cas9 in HEK293T cells to assess their activity and
specificity.
The capacity of gRNAs to induce site-specific DNA cleavage was as-
sessed by documenting non-homologous end joining (NHEJ) at the
targeted region. Indeed, gRNAs can induce targeted DNA DSBs,
which can be repaired by the NHEJ pathway in the absence of a
recombination template. This results in the introduction of small in-
sertions or deletions (indels) at the target locus, which can be scored
by the Surveyor mismatch-sensitive cleavage assay (Figure 1B). To
evaluate the activity of gRNAs, HEK293T cells were transfected
with similar doses of gRNA-encoding plasmids together with Cas9
nuclease. NHEJ was monitored 72 hr after transfection. GenomicDNA was extracted, and the targeted region was amplified by PCR
and subjected to the Surveyor nuclease (Figure 1C).
Among the five gRNAs tested, four showed up to 26% activity in
HEK293T cells. Only gRNA N2 did not show activity in HEK293T
cells. These four active gRNAs were then cloned into an HIV-derived
lentiviral vector (lentiCRISPR-v2) and delivered as integration-defi-
cient lentiviruses (IDLVs) in order to efficiently transduce primary
RDEB-Ks and RDEB-Fs. Similarly, HEK293T cells, RDEB-Ks, and
RDEB-Fs were transduced with IDLVs encoding for gRNA N1, N3,
N4, or N5 at the dose of 1.5 pg p24/cell, and gene modification fre-
quency was monitored at day 3 after transduction. Significant differ-
ences in NHEJ rates were observed. Among the four site-specific
gRNAs tested, only gRNAs N1 and N4 showed activity in
HEK293T cells (32% and 7%), in primary RDEB-Ks (18% and
15%), and in RDEB-Fs (15% and 8%) when delivered as IDLVs,
respectively (Figures 1D–1F). We observed no activities of gRNAs
N3 and N5 delivered as IDLVs, which could be explained by (1)
the possibility that the gRNA in the context of an IDLV genome in
the pre-integration complex of lentiviral vectors has a limited stability
in contrast to transfected naked plasmid DNA in cells, and (2) ineffi-
cient IDLV packaging.
In addition, we assessed NHEJ induced by the gRNA N1 encoding
IDLVs by Sanger sequencing and Tracking of Indels by Decomposi-
tion (TIDE) analysis, and we found similar targeting efficiencies esti-
mated to be 32.3% and 29.3% in RDEB-Ks and RDEB-Fs, respectively
(Figures 1G and 1H). Discrepancies between values of the NHEJ fre-
quency evaluated by the Surveyor cleavage assay and the TIDE assay
may be explained by the underestimation of NHEJ activity when us-
ing the Surveyor assay, which is less sensitive than the TIDE assay.20
Overall, gRNAN1 showed the highest activity in transduced cells, and
it was, therefore, considered for further gene correction experiments.
Genetic Correction of COL7A1 c.189delG Mutation by
CRISPR-Mediated HDR in Primary RDEB-Ks and RDEB-Fs
To achieve efficient correction of the c.189delG (p.Leu64Trpfs*40)
null mutation in exon 2, primary RDEB-Ks and RDEB-Fs, from a
patient homozygous for this mutation, were treated with increasing
doses of IDLVs encoding gRNAN1 together with the Donor template
and analyzed at 21 days post-transduction (Figure 2A). This late time
point was considered to avoid episomal expression of IDLVs encod-
ing the Donor template during the first days of treatment, which is
gradually lost by dilution in dividing cells after transduction.21
Genomic DNA was extracted and gene correction was investigated
on bulk-transduced cells using two strategies: allele-specific genomic
PCR and droplet digital TaqMan PCR. The first strategy detects only
HDR events because the PCR primers are specific for the genomic
sequence (at their 50 end) and the modified Donor sequence (at their
30 end) beyond the HDR junction. Gene correction occurred only in
primary RDEB-Ks and RDEB-Fs treated with both LV-CRISPR-
N1- and LV-Donor-encoding IDLVs (LV-CRISPR-N1, 1.5 or 2 pg
p24/cell; and LV-Donor, 0.5 pg p24/cell). In contrast, untreated cells
did not show the presence of the corrected band (Figure 2B). DirectMolecular Therapy: Nucleic Acids Vol. 12 September 2018 555
Figure 1. Design and Evaluation of the Cleavage Activity of gRNAs
Targeting COL7A1 Exon 2
(A) Sequences of the human COL7A1 exon 2 showing the location of five
different gRNAs (N1–N5; colored and underlined in violet, gray, blue, green,
and red) upstream or downstream of the c.189delG mutation. (B) PCR
strategy for the Surveyor cleavage assay. Top: target sites of gRNAs
(arrowheads) located in exon 2 are shown. Arrows indicate forward and
reverse PCR primers generating the 684-bp amplicon. Bottom: surveyor
cleavage theoretically produces the following bands: 305 and 379 bp for
gRNA N1, 293 and 391 bp for gRNA N2, 340 and 344 bp for gRNA N3, 240
and 444 bp for gRNA N4, and 318 and 366 bp for gRNA N5. (C) Evaluation
of the activity of gRNAs specific for exon 2 delivered together with Cas9
nuclease by plasmids. HEK293T cells were transfected with both plasmids,
one encoding for each of the gRNAs and the second encoding for the Cas9
nuclease. 72 hr later, gDNA was extracted and analyzed with the Surveyor
cleavage assay. Up to 22% of NHEJ activity was scored for gRNAs except
gRNA N2. (D–F) Evaluation of the activity of gRNAs delivered by IDLVs.
HEK293T cells (D), primary RDEB keratinocytes (RDEB-Ks) (E), and fibro-
blasts (RDEB-Fs) (F) were treated with IDLVs containing Cas9 together with
gRNA (N1, N3, N4, or N5) and similarly analyzed 72 hr later. Arrowheads
indicate the cleaved bands. Only gRNAs N1 and N4 showed NHEJ activity
when delivered by IDLVs. The percentage of modification by NHEJ (indels)
indicated below each lane was determined by densitometry. nd, non-de-
tected. (G and H) Evaluation of the cleavage activity of gRNA N1 encoding
IDLVs by Sanger sequencing followed by TIDE analysis in RDEB keratino-
cytes (RDEB-Ks) (G) and fibroblasts (RDEB-Fs) (H). (I) Comparison of the
cleavage activity of gRNA N1 estimated by the Surveyor (Cel I) and TIDE
assay with p values according to Student’s t test. Values are represented as
mean ± SD; *p = 0.0243 for RDEB-Ks and *p = 0.03 for RDEB-Fs. Each
experiment was repeated 3 times.
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Figure 2. CRISPR/Cas9-Mediated HDR at the COL7A1 Locus
(A) Top: design of the lentiviral vectors (LV-CRISPR-N1 encoding for gRNA N1
together with Cas9 and LV-Donor encoding for a promoterless Donor construct
containing homology sequences spanning the regions between introns 2 and 4).
In this construct, the 6-bp tag inserted in intron 2 allows allele-specific amplification
after HDR). Middle: COL7A1 genomic organization encompassing mutated exon 2.
Bottom: structure of corrected COL7A1 after CRISPR/Cas9-mediated HDR.
Arrows indicate the location of primers for corrected allele-specific genomic PCR.
(B) Genomic PCR analysis of the edited COL7A1 locus. Primary RDEB-Ks and
RDEB-Fs were transduced with the indicated doses of virus (pg p24 per cell), and
the gDNA was extracted at 21 days post-transduction and analyzed by PCR.
A specific 0.8-kb band corresponding to the corrected allele was amplified when
using P1/P3 primers. No specific amplification was detected in mock (untreated)
cells, as expected. The GAPDH gene was used as a reference. (C) Sequencing of
the PCR product generated with the P1/P3 primers from gene-edited RDEB-Ks
revealed genetic correction of the c.189delG mutation through CRISPR/Cas9-
mediated HDR.
www.moleculartherapy.orgsequencing of the PCR product from RDEB-Ks generated with the
P1/P3 primer set confirmed restoration of the normal genomic
sequence (Figure 2C).
The second strategy combines a TaqMan assay with the recently
developed ultra-sensitive droplet digital PCR (ddPCR) technology,
and it allows performing an absolute quantification of COL7A1 edit-
ing after CRISPR/Cas9-mediated HDR at the gDNA level. The detec-
tion sensitivity was estimated to be as low as 0.02%.22 For this assay,
we designed a common primer pair and allele-specific TaqMan
probes conjugated with FAM and VIC fluorophores that distinguish
between the corrected (target assay) and the mutated sequences
(reference assay), respectively (Figure 3A; Figure S1A). To screen
for COL7A1 editing, 50 ng genomic DNA from RDEB-Ks
and RDEB-Fs, transduced with increasing doses of virus (LV-
CRISPR-N1, 1.5 or 2 pg p24/cell; and LV-Donor, 0.5 pg p24/cell),
was subjected to TaqMan-ddPCR. The assay was performed in duplex
conditions (FAM and VIC probes were added in the same reaction
per sample), and the allelic frequency of the corrected COL7A1
(FAM+) and the mutated COL7A1 (VIC+) was investigated. Gene-
edited alleles (FAM+) were easily detected and quantified by Quanta-
Soft software (Figures 3B–3D; Figures S1B and S1C). Transduced
RDEB-Ks showed 13.3% and 19.6% of editing (wells N1 and N2),
and transduced RDEB-Fs showed 20% and 22% of editing (wells
N3 and N4), depending on the doses of IDLVs. A very small number
of positive droplets, found for the sample with the DNA from un-
treated cells (well N5) or the sample without DNA template (well
N6), was considered to be false positives (Figure 3D).
Further, we performed TaqMan-ddPCR to evaluate the efficiency of
COL7A1 correction at the mRNA level (Figures S2A–S2D). For this
assay, we used two probes: the target probe (FAM labeled), which rec-
ognizes the correctedCOL7A1 (the same as described above, Figure 3),
and the reference probe (VIC labeled), which recognizes the house-
keeping RPLP0 gene. The percentage of the corrected COL7A1 tran-
script in RDEB-Ks (well N1) and RDEB-Fs (well N5) was calculated
to be 11% and 15.7%, respectively (Figure S2D). In contrast, cells
treated only with the Donor (wells N2 and N6) did not show signif-
icantly positive amplification, while untreated cells (wells N3 and N7)
were completely negative (Figures S2B–S2D).
Rescue of Type VII Collagen Expression in Gene-Edited
RDEB-Ks and RDEB-Fs
To investigate restoration of type VII collagen expression after
CRISPR/Cas9-mediated HDR, we performed western blotting and
immunocytochemistry analysis on transduced primary RDEB-Ks
using anti-type VII collagen LH7.2 antibody (Figure 4). First, we as-
sessed C7 protein expression and secretion in gene-corrected cells
versus normal human keratinocytes (NHKs) treated with increasing
doses of IDLVs encoding for the LV-CRISPR-N1 and the Donor
template. Intracellular C7 protein expression was detected from cell
extracts (Figure 4A) and was estimated to be 10.66% and 11%
(compared to C7 expression in NHKs), depending on the doses of
IDLVs (LV-CRISPR-N1, 1.5 or 2 pg p24/cell; and LV-Donor,Molecular Therapy: Nucleic Acids Vol. 12 September 2018 557
Figure 3. TaqMan-ddPCR-Based Detection of CRISPR/Cas9-Mediated HDR at the COL7A1 Locus
(A) Gene editing detection strategy forCOL7A1 by ddPCR on the gDNA level. The location of a common primer pair and allele-specific probes conjugated with FAM (specific
for the corrected COL7A1) or VIC (specific for the mutated COL7A1) fluorophores are indicated. (B) Primary RDEB-Ks and RDEB-Fs were transduced with the indicated
doses of IDLVs (pg p24 per cell). 21 days post-transduction, gDNAwas extracted, amplified, and analyzed by ddPCR to assess allelic frequency of correctedCOL7A1 on the
mutated background. 1D fluorescence amplitude plots are shown for FAM and VIC signals. Blue dots correspond to the FAM signal amplitude and represent droplets
containing the corrected COL7A1 alleles. Green dots correspond to the VIC signal amplitude and represent the mutated COL7A1 alleles. Gray dots correspond to empty
droplets. Yellow lines indicate borders between different samples. (C and D) Quantification of positive droplets using Quantasoft Software. The concentration plot (C),
showing gene-edited wells of FAM and VIC amplicons, is automatically determined by the software using the total number of events (displayed in Figure S1C) by correcting for
Poisson distribution. The blue markers indicate corrected COL7A1 copies/mL and the green markers indicate mutatedCOL7A1 copies/mL. The fractional abundance plot (D)
shows the percentage of frequency of the corrected COL7A1 on the mutated COL7A1 background. All error bars were generated by QuantaSoft and represent a 95%
confidence interval.
Molecular Therapy: Nucleic Acids0.5 pg p24/cell) (Figure 4A). In parallel, C7 protein secretion was de-
tected from conditioned media (Figure 4B), when high doses of virus
were used (LV-CRISPR-N1, 2 pg p24 per cell). In contrast, untreated
RDEB cells were negative for C7. Rescued C7 expression was also
confirmed by immunocytochemistry on primary RDEB-Ks and fibro-
blasts, co-treated with the IDLVs encoding for LV-CRISPR-N1
and the Donor template, whereas untreated RDEB cells (mock)
completely lacked C7 (Figure 4C). Thus, COL7A1 editing and desired
phenotypic correction (up to 11%) could be achieved in primary
RDEB-Ks and RDEB-Fs by HDR through combined gRNA- and
Donor-encoding IDLV delivery.
In parallel, to evaluate whether non-integrative lentiviral vector-based
gene correction modifies the morphology and the proliferative capac-
ity of transduced primary RDEB-Fs, we monitored gene-corrected
fibroblast growth and confluence using the IncuCyte live-cell-imag-
ing system. Corrected RDEB-Fs showed a selective advantage of pro-
liferation in comparison with untreated RDEB-Fs or RDEB-Fs treated
only with Donor-encoding IDLVs (Figure 4D). No difference in558 Molecular Therapy: Nucleic Acids Vol. 12 September 2018morphology was found between normal human fibroblasts (NHFs)
and treated or untreated RDEB-Fs (data not shown).
We have also investigated the regenerative capacity of gene-corrected
RDEB-Ks by performing a colony-forming efficiency assay.We found
that the lentiviral vector-based transduction did not impair the
keratinocyte proliferative capacity in comparison with untreated
RDEB-Ks (Figure 4E).
Analysis of Off-Target Sites and the Persistence of Cas9 in
Gene-Edited RDEB Cells
To investigate whether gRNA N1 triggers potential off-targets in
edited RDEB cells, we looked for human genomic sequences display-
ing significant homology with the cognate site. Potential off-target
sequences for gRNA N1 were identified by ZiFiT Targeter 4.2
(http://zifit.partners.org) in the human genome, and only 3 potential
off-targets (Off-Targets_1,2,3) were found with 2 mismatches (MMs)
in non-coding regions. Off-target prediction using http://crispr.mit.
edu identified 3 additional potential off-targets with 3 MMs
Figure 4. Restoration of Type VII Collagen Expression in Gene-Edited RDEB Keratinocytes and Fibroblasts
(A) Western blot analysis showing C7 re-expression in lysates from gene-edited RDEB-Ks using the LH7.2 anti-C7 antibody. Antibody to b-actin served as the loading control.
(B) Western blot analysis showing secreted C7 in conditioned medium from gene-edited RDEB-Ks using the LH7.2 anti-C7 antibody. Normal human keratinocytes (NHKs)
show a normal level of C7 expression in lysates and in conditionedmedium. (C) Gene-edited RDEB-Ks and RDEB-Fs 21 days post-transduction, positively stained for type VII
collagen. Untreated (mock) cells show negative staining for C7 as expected. Scale bars, 50 mm. (D) Gene-edited fibroblast growth and confluence monitoring using IncuCyte.
NHFs, untreated primary RDEB-Fs, and RDEB-Fs treated with CRISPR-N1 together with or without the Donor-encoding IDLVs were seeded in 12-well plates andmonitored
during 8 days. Data were analyzed using IncuCyte S3 basic analyzer software. NHF confluence monitoring is presented in dark blue or pink. Corrected RDEB-Fs (in green)
show selective advantage of proliferation in comparison with untreated RDEB-Fs (in light blue) or RDEB-Fs treated only with Donor-encoding IDLVs (in yellow). (E) Colony-
forming efficiency assay on gene-corrected RDEB keratinocytes and untreated RDEB keratinocytes 21 days post-transduction at a density of 500 (upper panel) or 100 cells
(lower panel) in 10-cm Petri dishes coated with irradiated 3T3-J2 MEF as a feeder layer.
www.moleculartherapy.org(Off-Targets_4,5,6) and 2 potential off-targets with 4 MMs (Off-
Targets_7,8) in coding regions (Figure 5A). Thus, to determine if
the COL7A1-specific gRNA N1 was able to induce DSBs at non-
specific loci bearing partial homology with the endogenous target
sequence listed above, RDEB cells were treated with the gRNAN1-en-
coding IDLVs (1.5 pg p24 per cell), genomic DNA was extracted at
2 days post-transduction, and regions corresponding to these 8 off-
target sequences were amplified by PCR and digested by the Surveyor
nuclease. Results showed no evidence for non-specific cleavage
(350-bp expected band after digestion) of selected off-target hits
at sites with partial homology (Figure 5B). Moreover, no evidence
for non-specific cleavage of the same off-target hits was found in
genetically corrected RDEB-Ks 21 days post-transduction (Figure S3).To investigate the persistence of Cas9 in genetically corrected cells
after transduction, we performed absolute quantification assay, and
we found very few copies of Cas9 cDNA in these cells. Up to 1.8
Cas9 copies/mL were found in bulk-transduced cells, corresponding
to 2.25  106 and 3.81  106 Cas9 copies/cell in RDEB-Ks and
RDEB-Fs, respectively. To investigate the persistence of Cas9 in
genetically corrected cells after transduction, we performed absolute
quantification assay, and we found very few copies of Cas9 cDNA
(up to 1.8 copies/mL) in these cells. This may be explained by the
fact that episomal or integrated forms of IDLVs could be still present
in these cells 21 days post-transduction. Importantly, we found no ev-
idence for the persistence of residual Cas9 cDNA in genetically cor-
rected skin equivalents (SEs) 1 and 2 months post-grafting (Table S2).Molecular Therapy: Nucleic Acids Vol. 12 September 2018 559
Figure 5. Off-Target Site Analysis
(A) Potential off-target cleavage hits for the gRNAN1were
identified by ZiFiT Targeter 4.2 in the human genome.
Mismatches (MMs) are underlined. Note that there is no
off-target with 1 MM. 3 potential off-targets were found
with 2 MMs in non-coding regions. In addition, 3 potential
off-targets with 3 MMs and 2 potential off-targets with
4 MMs were identified in coding regions. The 8 off-target
sequences were subjected to the Surveyor cleavage
assay. (B) Genomic DNA from RDEB-Ks treated with
IDLVs encoding for the LV-CRISPR-N1 (2 pg p24 per cell)
was extracted, and regions corresponding to off-target
sequences were amplified by PCR using specific primers
(listed in Table S4). The Surveyor cleavage assay was
performed at each potential off-target hit. No Surveyor
activity indicative of cleavage at predicted off-target sites
was detected. nd, non-detected.
Molecular Therapy: Nucleic AcidsEx Vivo Functional Correction of Type VII Collagen and AF
Formation at the Dermal-Epidermal Junction
To assess functionality of type VII collagen in gene-corrected
RDEB-Ks and RDEB-Fs, we produced 3D SEs and analyzed them
in a human: murine xenograft model. Three groups of SEs were
produced and grafted onto the dorsal region of immunodeficient
mice using a skin flap procedure as previously reported.23,24 The
first group was composed of primary NHKs and NHFs, the second
was composed of corrected primary RDEB-Ks and RDEB-Fs,
and the third was composed of untreated primary RDEB-Ks and
RDEB-Fs. At 4 and 10 weeks later, skin grafts were removed
and subjected to immunofluorescence, molecular, and ultrastruc-
tural analysis.
Immunofluorescence analysis on the serial sections of skin grafts
composed of genetically corrected primary RDEB-Ks and RDEB-Fs
showed C7 rescue and linear localization at the dermal-epidermal
junction similar to the normal skin (Figure 6A; Figure S5). In
contrast, skin grafts made from untreated RDEB-Ks and RDEB-Fs
were totally devoid of C7. Up to 26% of C7 rescue was found at
the dermal-epidermal junction in skin grafts by quantifying mean
fluorescence intensity of type VII collagen stained with LH7.2 anti-
body (Figure 6C, gray bars). At the genomic DNA level, up to 19% of
COL7A1 editing was found on cryosections of skin grafts by ddPCR
(Figure 6C, blue bars; Figure S6). A very small number of positive
droplets found in the sample of skin grafts composed of untreated
cells or in the sample without DNA template (non-treated control
[NTC]) was considered to be false positive (Figure S6). Finally, anal-
ysis of ultrathin sections of genetically corrected skin grafts by trans-
mission electron microscopy revealed the presence of structures
characteristic of AFs at the dermal-epidermal junction (Figure 6B).
They showed funning and central cross-banding structures forming
loops around dermal collagen fibers and inserted into the lamina
densa, similar to AFs seen in healthy skin grafts composed of560 Molecular Therapy: Nucleic Acids Vol. 12 September 2018NHKs and NHFs. In contrast, RDEB skin grafts composed of un-
treated cells showed no evidence for AFs (Figure 6B).DISCUSSION
Recently developed gene-, cell-, protein-, or bone marrow transplan-
tation- based strategies for DEB have shown therapeutic potential
with variable efficacy and safety.23–29 The first successful gene therapy
report for junctional EB (JEB) caused by LAMB3 mutations used
autologous grafts of epithelial sheets genetically corrected with a clas-
sical g-retroviral vector expressing LAMB3 cDNA.30 Recently, the
same vector was used to genetically correct keratinocytes of a
7-year-old child suffering from JEB. He was almost entirely (80%)
grafted with autologous genetically corrected epidermal sheets and
showed fully functional epidermis.31 Specifically, gene addition
approaches for RDEB currently involve self-inactivating (SIN) lenti-
virus- or retrovirus-mediated transfer of COL7A1 cDNA into kerati-
nocytes and/or fibroblasts and transplantation of corrected epithelia
or SEs with restored type VII collagen protein expression, leading
to AF formation and recovering of dermal-epidermal adher-
ence.24,27,32 A phase 1 ex vivo gene therapy clinical trial for RDEB
using transplantation of autologous epithelial sheets genetically
modified with a classical retroviral vector expressing COL7A1
cDNA was conducted at Stanford.27 Among four patients treated,
three showed improved wound healing of grafted sites and type VII
collagen expression localizing to AFs at the dermal-epidermal base-
ment membrane at least 1 year post-treatment, without significant
adverse events.
In several pre-clinical studies, the therapeutic potential of intra-
dermally injected gene-corrected RDEB-Fs was also investigated.
Intradermal injections of RDEB-Fs genetically corrected with a
therapeutic-grade SIN lentiviral vector, encoding codon-optimized
COL7A1, showed functional restoration and AF formation at the
Figure 6. Type VII Collagen Rescue, Localization, and AF Formation at the Dermal-Epidermal Junction in Genetically Corrected Skin Grafts
(A) Immunofluorescence analysis of grafted SE composed of normal, RDEB, or genetically corrected primary RDEB keratinocytes and fibroblasts at 1 or 2 months after
deflapping. Skin samples composed of genetically corrected cells showed re-expression and normal localization of C7 at the dermal-epidermal junction in contrast to skin
samples composed of untreated RDEB keratinocytes and fibroblasts, totally devoid of C7. Scale bars, 50 mm. (B) Ultrastructural analysis of skin grafts by transmission
electron microscopy (TEM). Anchoring fibrils showing thick, cross-binding structural characteristics inserted into lamina densa were found in skin samples composed of
genetically corrected cells at 1 or 2 months after deflapping. Anchoring fibrils are indicated by red arrows. Scale bars, 200 nm. (C) Percentage of C7 correction in skin grafts
quantified by ddPCR (blue bars, see also Figure S3) and by mean intensity of fluorescence using ImageJ software (gray bars).
www.moleculartherapy.orgdermal-epidermal junction in human RDEB skin xenografts on
NOD-scid IL2Rgamma-null mice.29 Our group showed that intrader-
mal injections of genetically corrected RDEB-Fs using a SIN retroviralvector also showed functional restoration and AF formation at the
dermal-epidermal junction in a xenograft RDEB SE model in nude
mice.23 Both vectors have been proposed for clinical trials using localMolecular Therapy: Nucleic Acids Vol. 12 September 2018 561
Molecular Therapy: Nucleic Acidsintradermal injections of autologous gene-corrected fibroblasts.
Although the use of SIN vectors considerably reduces the risks of
cell transformation by oncogene activation, aberrant splicing, epige-
netic modifications, or progressive extinction of the therapeutic trans-
gene may still occur.33,34
In this context, gene correction approaches based on sequence-spe-
cific DSB-mediated HDR offer a major advantage in the field of
gene therapy as compared to conventional strategies.35,36 They allow
precise correction of disease-causing mutations restoring physiologic
expression and function of the gene by preserving the endogenous
transcriptional regulation.37 Recently, gene editing proof-of-concept
approaches were successfully achieved in RDEB15–17 as well as in
HIV infection, alpha-1 antitrypsin (AAT) deficiency, cystic fibrosis,
Duchene muscular dystrophy, X-linked severe combined immunode-
ficiency syndrome, hemophilia B, sickle cell anemia, and Fanconi ane-
mia.38–44 Finally, nuclease-mediated HDR has been shown to bemore
effective in iPSCs than in primary skin cells, which could open new
perspectives for the treatment of RDEB and various other genetic
diseases.45,46 Such genetically corrected cells could then be used to
generate 3D SEs to demonstrate functional and sustained correction
through type VII collagen protein expression and AF formation.47–49
The relevance of iPSCs combined with gene correction approaches
has been demonstrated in two RDEB murine models,50,51 in naturally
occurring revertant human RDEB-Ks,52 and in fibroblasts from
DDEB patients.53
In our study, we provide evidence for efficient functional COL7A1
repair by using patient’s primary keratinocytes and fibroblasts.
The homozygous c.189delG (p.Leu64Trpfs*40) null mutation in
exon 2 selected for this study was identified in several RDEB pa-
tients with severe generalized RDEB (unpublished data). We used
IDLVs to deliver the specific gRNA together with Cas9 nuclease
and the Donor template in RDEB cells as these vectors have been
previously reported as being effective to achieve homologous recom-
bination in human epithelial stem cells.54 The exon2-specific gRNA
that we designed led, in the presence of the repair template, to the
genetic correction of the COL7A1 mutation and to functional resto-
ration of type VII collagen expression. Analyses at the cDNA and
protein levels showed evidence for precise editing at the mutated
locus with 11% and 15.7% of corrected COL7A1 transcripts in
transduced primary keratinocytes and fibroblasts, respectively. In
our study, the Surveyor (Cel 1) cleavage assay indicated the absence
of a detectable level (threshold >1%–5%) of off-target gene modifi-
cation. In fact, to avoid or to limit these events, we used gRNAs with
improved design (high specificity score and short size; 17- to 18-bp
length instead of 20 nt).19 However, genome-wide analysis of off-
targeting is necessary before clinical translation, as non-specific
targeting can cause genome instability and disruption of a normal
gene function.55–57 The use of high-fidelity or SIN Cas9 nucleases
(spCas9-HF1, eSpCas9_1.1, HypaCas9, KamiCas9),57–60 Cas9
nickase instead of nuclease,61,62 or recently described Adenine
base editors (ABEs convert A*T to G*C) could be considered to
reduce off-target breaks.63562 Molecular Therapy: Nucleic Acids Vol. 12 September 2018To our knowledge, only low efficiency of gene correction (2%–4%)
could be achieved through MN- or TALEN-mediated HDR in pri-
mary RDEB cells or immortalized keratinocyte cell lines without
selection.15,16 Recently, COL7A1 editing was also obtained through
CRISPR/Cas9-mediated HDR in a RDEB-K cell line using antibiotic-
and fluorescence-based selection. Type VII collagen rescue was
demonstrated in skin grafts composed of genetically corrected
immortalized keratinocytes, but there was no evidence of AF forma-
tion at the dermal-epidermal junction.18 It is believed that R35% of
normal C7 levels are necessary for skin mechanical stability based on
wild-type (WT) fibroblast injection experiments in a DEB hypomor-
phic murine model.28 In our study, we could demonstrate that re-
expression of COL7A1 transcripts estimated to be up to 11% and
15% in RDEB cells and up to 19% in skin grafts was sufficient to allow
AF formation with no dermal-epidermal separation.
Most likely explanations include the following: (1) in vivo positive
selection of C7-expressing epidermal clones (Figure 4C), (2) local
diffusion of C7 at the sites of synthesis (Figure 6A; Figure S5), and
(3) possible contribution of gene-corrected fibroblasts with increased
capacities of proliferation (Figure 4D). Of note, gene-edited keratino-
cytes prior to transplantation showed 11% of COL7A1 correction at
the genomic DNA level, as shown by ddPCR (Figure S2D). These cells
expressed up to 11% of C7 on western blot (Figures 4A and 4B).
Following transplantation, immunofluorescence of gene-corrected
SEs showed 20%–26% of C7 expression in a continuous linear
staining pattern along the dermal-epidermal junction (Figure 6A).
In addition, droplet PCR of genomic DNA extracted from skin
sections of grafted gene-corrected RDEB SEs showed up to 19% of
COL7A1 correction (Table S3). These results are in favor of local
diffusion of C7 at the sites of synthesis and its accumulation at the
dermal-epidermal junction.
Moreover, we did not find evidence for the persistence of residual
Cas9 expression in genetically corrected SEs 1 and 2 months post-
grafting (Table S2).
Overall, our data provide evidence for efficient and functional ex vivo
correction of COL7A1 in a human: murine xenograft model. There-
fore, precise genome editing for RDEB is a new and promising strat-
egy to correct COL7A1 recurrent mutations and sequences located
nearby, for the development of future ex vivo clinical applications.
MATERIALS AND METHODS
gRNA Design and Plasmid Construction
gRNAs were designed using the ZiFiT Targeter 4.2 (http://zifit.
partners.org) online software. Five gRNA (N1–N5) sequences target-
ing COL7A1 (Table S1) were cloned into the plasmid MLM3636
(Addgene 43860) according to the available guidelines. The activity
of gRNAs was tested using the plasmid PX165 encoding for the hu-
man codon-optimized Cas9 nuclease from Streptococcus pyogenes
(SpCas9) (Addgene 48137). Selected gRNAs displaying activity
in HEK293T cells were cloned into the plasmid lentiCRISPR_v2
(Addgene 52961) according to the available guidelines to efficiently
www.moleculartherapy.orgtransduce RDEB-Ks and RDEB-Fs. The LV-Donor lentiviral vector,
used for gene-targeting experiments, was described previously.16
Lentiviral Vector Production and Titration
gRNAs and theDonor templatewere delivered as IDLVs, pseudotyped
with the vesicular stomatitis virus G protein (VSV-G) envelope glyco-
protein. Lentivirus production was performed as described previ-
ously.64 Briefly, HEK293T cells were transfected with the relevant len-
tiviral construct (LV-CRISPR-N1, LV-CRISPR-N3, LV-CRISPR-N4,
LV-CRISPR-N5, or LV-Donor) and packaging plasmids pBA-Rev,
p-Tat, p-MDG, or p-HDMHg/pM2-D64L (for IDLV production) by
calcium phosphate precipitation. Culture media were harvested after
48 and 72 hr, passed through a 0.45mm filter (Millipore), and ultracen-
trifuged at 100,000 g for 2 hr. Pellets were re-suspended in PBS-BSA
1% and stored at 80C. For lentivirus titration, p24Gag was
measured using the QuickTiter lentivirus titer kit (Euromedex).
Lentivirus titer was calculated according the general guideline of
1 ng p24 = 105 transducing units (TUs). Yield ranged from 1 to
10 mg/mL p24 corresponding to 108–109 TUs/mL.
Assessment of CRISPR/Cas9 Activity by Surveyor Cleavage
Assay and TIDE Analysis
The capacity of gRNAs to induce DSBs at its target site was evaluated
by Surveyor cleavage assay (Integrated DNA Technologies), accord-
ing to the manufacturer’s instructions. Briefly, HEK293T cells and
primary RDEB-Ks and RDEB-Fs were transduced with 1.5 pg (p24/
cell) gRNA-Cas9-encoding IDLVs. After 72 hr, genomic DNA was
extracted using Genomic DNA from tissue kit (Macherey-Nagel),
and a 0.7-kb region flanking the gRNA target site was amplified by
PCR (Phusion high-fidelity DNA polymerase, New England Biolabs)
using specific primers (see Table S4). The following conditions for
amplification were used: 98C for 2 min; then 29 cycles at 98C for
30 s, 62C for 30 s, and 72C for 45 s; followed by extension at
72C for 5 min. Untreated cells were used as controls. 200 ng purified
PCR products were denatured, digested with the nucleotide-
mismatch-sensitive Cel1 endonuclease, and analyzed on 1.5% agarose
gel using ImageLab (Bio-Rad) software. The intensities of the bands
were quantified by ImageJ. The percentage of NHEJ was calculated
using the formula 100  (1  (1  fraction cleaved)1/2), where the
fraction cleaved is the ratio of the intensity of the cleaved bands
(digested bands) over the cleaved and un-cleaved bands for each
experimental setting.
In parallel, PCR products amplified from RDEB-Ks and RDEB-Fs
treated with IDLVs encoding for the gRNA N1 were sequenced by
Sanger and analyzed by the TIDE web tool (https://tide.nki.nl), as
initially described by Brinkman and colleagues.65
Cells
HEK293T cells and primary RDEB-Fs were maintained in DMEM
with Glutamax and 4.5 g/L glucose (Life Technologies) supplemented
with 10% fetal bovine serum (FBS) (Lonza) and 1% antibiotics (Life
Technologies). Primary RDEB-Ks were maintained in a keratinocyte
growth medium, a DMEM-Glutamax and Ham’s F12 (Life Technol-ogies) media mixture (3:1) containing 10% FBS, 1% antibiotics,
adenine (0.18 mM), insulin (5 mg/mL), hydrocortisone (0.4 mg/mL),
cholera toxin (0.1 nM), triiodothyronine (0.2 nM), and epidermal
growth factor (EGF, 10 ng/mL). Primary RDEB-Ks were plated on
lethally irradiated mouse 3T3-J2 fibroblasts and grown in keratino-
cyte growth medium (before and after transduction) or cultivated
in Epilife medium (after transduction) with 0.06 mM calcium and
human keratinocyte growth supplement (HKGS) containing a final
concentration of 0.2% bovine pituitary extract (BPE), 5 mg/mL bovine
trasferrin, 0.18 mg/mL hydrocortisone, 5 mg/mL bovine insulin, and
0.2 ng/mL EGF (Life Technologies).
HDR Assay
Primary RDEB-Ks and RDEB-Fs were seeded at 105 cells/well in
12-well plates. The following day (or 2 days later only for primary
keratinocytes grown on irradiated 3T3J2 feeder layer), cells were
co-infected with the indicated doses of vectors in the presence of
8 mg/mL polybrene (Sigma-Aldrich). After 72 hr, cells were harvested,
reseeded in 6-well plates, and grown for at least 21 days.
Analysis of Genetically Corrected Cells by Allele-Specific PCR
Genomic DNA from transduced cells was isolated and 200 ng was
used for PCR to detect corrected ormutant allele after HDR. To inves-
tigate the correction of exon 2 in primary RDEB-Ks and RDEB-Fs, a
common P1 forward primer in combination with P2 or P3 specific
reverse primers was used to detect mutant or corrected allele, respec-
tively. The GAPDH gene was used as a reference (Table S4). The
following conditions for amplification were used: 98C for 2 min;
then 34 cycles at 98C for 30 s, 56C for 30 s, and 72C for 30 s; fol-
lowed by extension at 72C for 5 min. PCR products were analyzed on
1% agarose gel and imaged with ImageLab (Bio-Rad). Corrected
allele-specific PCR product from gene-corrected keratinocytes was
subjected to Sanger sequencing.
Analysis of Genetically Corrected Cells by TaqMan-ddPCR
For the TaqMan-ddPCR assay, sequences of designed primers and
probes specific for corrected and mutated COL7A1 are shown in
Table S4. The ddPCR assay was performed following the manufac-
turer’s instructions (Bio-Rad). Each ddPCR reaction consisted of a
20-mL solution containing 10-mL ddPCR supermix for probes (Bio-
Rad), 900 nM primer, 250 nM FAM-labeled probe, 250 nM VIC-
labeled probe, and 50 ng template DNA. About 20,000 droplets
were generated per reaction on the Bio-Rad QX-100 Droplet Gener-
ator. Then the emulsion was transferred into a 96-well PCR plate for
standard PCR on a T100 Thermal Cycler (Bio-Rad). The PCR pro-
gram was as follows: initial denaturation at 95C for 10 min, followed
by 40 cycles of melting at 95C for 30 s and annealing /extension at
60C for 1 min (Rampe Rate at 2C/s), and final enzyme deactivation
at 98C for 10 min. After cycling, the 96-well plate was immediately
transferred into the Bio-Rad QX-100 Droplet Reader, where flow cy-
tometric analysis determined the fraction of PCR-positive droplets
(blue and green dots) versus the number of PCR-negative (gray
dots) droplets in the sample. Data were analyzed by QuantaSoft Soft-
ware (Bio-Rad) using the RED (rare events detection) option. TheMolecular Therapy: Nucleic Acids Vol. 12 September 2018 563
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determined and corrected for Poisson distribution. All error bars
were generated by the software and represent 95% confidence interval.
To evaluate the efficiency of COL7A1 editing in transduced RDEB
cells after CRISPR/Cas9-mediated HDR, 50 ng genomic DNA of cor-
responding samples was subjected to ddPCR. The assay was per-
formed using primers and probes complementary to the corrected
or the mutated sequence in exon 2 of COL7A1 (custom design).
The allelic frequency of corrected versus mutated COL7A1 was deter-
mined in the fractional abundance plot, which shows the percentage
frequency of the corrected COL7A1 on the mutated COL7A1
background.
To evaluate the level of corrected COL7A1 mRNA expression, total
RNA was extracted from transduced primary RDEB cells using
RNeasy Mini Kit (QIAGEN), and cDNA was synthesized using
SuperScript IV First-Stand Synthesis System (Thermo Scientific).
Gene expression assay was performed using primers and probe
complementary to the corrected sequence in exon 2 of COL7A1
(as described above) and theRPLP0 (reference 99999902; Thermo Sci-
entific), the latter amplification used as normalizer. COL7A1 mRNA
was normalized to the housekeeping gene control RPLP0. No specific
amplification in RDEB-Ks and RDEB-Fs was found. The relative
expression level of the corrected COL7A1 mRNA was calculated on
the basis of the ratio plot (concentration of COL7A1 versus RPLP0)
by considering it in normal cells (NHKs and NHFs) as 100%.
Western Blot Analysis
For intracellular detection of C7, keratinocytes grown in the presence
of 20 ng/mL transforming growth factor b2 (Abcam, Cambridge, UK)
were lysed in a buffer, containing 150 mmol/L NaCl, 50 mmol/L Tris-
HCl (pH 8), 5 mmol/L EDTA, 1% NP40, and complete mini protease
inhibitor cocktail (Roche, Basel, Switzerland), 72 hr after transduc-
tion. Supernatants were precipitated by the addition of 3 vol cold
acetone and incubated at20C for 48 hr. The following day, precip-
itated proteins were pelleted by centrifugation and solubilized in
a Tris-Urea (25-mmol/L, 9.5-mol/L) buffer. 60 mg proteins in a
4 Laemmli buffer was loaded, denatured at 70C for 10 min, sepa-
rated on 3%–8% precast SDS-PAGE gels (Life Technologies), and
transferred to nitrocellulose membrane. The LH7.2 antibody was
used (1:1,000) to detect type VII collagen. b-actin immunodetection
served as a loading control. Signals were revealed with ECL-plus
reagent (Thermo Scientific) using ImageLab software (Bio-Rad).
For the detection of secreted C7, keratinocytes were grown for 48 hr
in the presence of 20 ng/mL transforming growth factor b2 and
50 mg/mL ascorbic acid in a serum-free keratinocyte growth medium.
The medium was collected, precipitated, and analyzed using LH7.2
antibody as described above.
IncuCyte Live-Cell Imaging
Gene-corrected fibroblast morphology and proliferation were investi-
gated using the IncuCyte live-cell imaging device available at Imagine564 Molecular Therapy: Nucleic Acids Vol. 12 September 2018Institute. Briefly, primary NHFs from two different donors, RDEB-Fs
treated with LV-CRISPR-N1 and LV-Donor, RDEB-Fs treated only
with LV-Donor, and untreated RDEB-Fs were seeded at 104 cells/
well in 12-well plates and monitored during 8 days for confluence
and proliferation. Cells were seeded in triplicates. Five independent
regions were scanned for each well every 6 hr during 8 days with
the live-cell-imaging system (phase-contrast, objective 4). Data
were analyzed using the IncuCyte S3 basic analyzer software.
Colony-Forming Efficiency Assay
Untreated and genetically corrected RDEB-Ks (initially at 21 days
post-transduction corresponding to passage 8) were analyzed for their
regenerative capacity by using the colony-forming efficiency assay
originally developed by Rochat and colleagues.66 Briefly, untreated
and genetically corrected RDEB-Ks were plated for three consecutive
passages (at passages 9, 10, and 11) at a density of 500 or 100 cells in
10-cm Petri dishes coated with irradiated 3T3-J2 murine embryonic
fibroblast (MEF) as a feeder layer. After 13 days of culture, clones
were fixed, stained with 1% rhodamine, counted under a dissecting
microscope, and quantified for their growth potential.
Absolute Quantification of Residual Cas9 Transcript Level in
Genetically Corrected Cells and Grafted SEs
To evaluate the persistence of Cas9 cDNA in cells after IDLV trans-
duction, total mRNA was extracted using the RNeasy Mini Kit
(QIAGEN) from bulk transduced cells (RDEB-Ks and RDEB-Fs)
and from grafted SEs. cDNA was synthesized using SuperScript III
First-Stand Synthesis System (Thermo Scientific). Real-time qPCR
was performed on the ABI prism 7300 Real Time Detection system
(Applied Biosystems), according to the manufacturer’s instructions.
The absolute quantification assay using SYBR green Dye 1 was per-
formed in triplicate using primers specific for Cas9 (Table S2).
To generate a standard curve, a 100-fold serial dilution series of the
lentiCRISPR_v2 plasmid DNA, ranging from 1 to 109 copies/mL,
was used. The concentration of the plasmid was measured, and the
corresponding copy number was calculated by the following equa-
tion: plasmid DNA (copy) = 6.02  1023 (copy/mol)  plasmid
DNA amount (g)/plasmid DNA length (bp)  660 (g/mol/bp). The
Ct values were plotted against the logarithm of their initial template
copy numbers. The standard curve was generated by linear regression
of the plotted points. PCR amplification efficiency (E) of the Cas9-
specific primer set was calculated according to the equation
E = 101/slope – 1. From the slope, a high amplification efficiency of
99% was determined for Cas9 primers.
Cas9 expression in transduced cells and in grafted SEs was evaluated
in triplicates. Three independent experiments were performed.
Values corresponding to Cas9 copies/mL were converted to values of
Cas9 copies/cells, taking into consideration two criteria, the initial
number of cells subjected to mRNA extraction and the amount of
mRNA used for the cDNA synthesis, as follows: (1) up to 3.2  106
RDEB-Ks (200 ng/mL) and up to 1.5  106 RDEB-Fs (150 ng/mL)
www.moleculartherapy.orgwere subjected to mRNA extraction, which was recovered in 20 mL;
thus, the mRNA concentration corresponds to 160,000 and 75,000
cells/mL for RDEB-Ks and RDEB-Fs, respectively; (2) up to 1 mg
RNA was used for cDNA synthesis, which corresponds to 5 and
6.6 mL for RDEB-Ks and RDEB-Fs, respectively; thus, 800,000
(RDEB-K) and 495,000 (RDEB-F) cells were used for cDNA synthe-
sis; and, (3) in RDEB-K samples, 1.39 and 1.8 Cas9 copies/mL were
found, which correspond to 2.25  106 and 1.73  106 Cas9
copies/cell; in RDEB-F samples, 1.89 and 1.87 Cas9 copies/mL were
found, which correspond to 3.81  106 and 3.7  106 Cas9
copies/cell.
Immunofluorescence Analysis
Gene-corrected and RDEB cells were grown for 48 hr in the presence
of 20 ng/mL transforming growth factor b2 (Abcam), fixed on meth-
anol, and stained with a monoclonal anti-C7 antibody (clone LH7.2)
(Sigma-Aldrich). C7 in primary RDEB-Ks and RDEB-Fs was detected
by using a fluorescein isothiocyanate (FITC)-conjugated goat-anti-
mouse secondary antibody. Cells in 3 independent experiments
were photographed and analyzed. For analysis of skin grafts, optimal
cutting temperature compound (OCT)-embedded cryosections were
fixed with acetone and stained with LH7.2 primary antibody against
C7. Fluorescence-mounting medium containing DAPI (0.5 mg/mL)
was used. Three different cryosections for each skin graft were
analyzed by immunostaining of C7, and images were captured with
a Leica TCS SP8 confocal microscope at the Cell Imaging facility of
Imagine Institute. Fluorescence intensity-based quantification of C7
was performed using ImageJ software. Three independent areas for
each sample were quantified for mean intensity of fluorescence.
Percentage of C7 rescue was calculated by considering the mean
fluorescence intensity in control skin grafts (composed of NHKs
and NHFs) as 100%.
SE Production and Grafting onto Nude Mice
SE production was performed as described previously with minor
modifications.23,24 For this study, three types of SEs were produced:
(1) control SE composed of primary NHKs and NHFs, (2) RDEB
SE made of patient-derived RDEB-Ks and RDEB-Fs, and (3) gene-
corrected RDEB SE made of patient-derived gene-corrected RDEB-
Ks and RDEB-Fs. Briefly, freeze-dried fibrinogen, obtained from hu-
man plasma of a blood donor, was reconstituted with 6 mL sterile PBS
and mixed with 1.5 106 fibroblasts in 16 mL DMEM supplemented
with 10% fetal calf serum, 42 mg/mL tranexamic acid, and 10 mg/mL
thrombin (Sigma-Aldrich). The fibrin-fibroblast mix was dispensed
into a 6-well culture plate, and a day later 1.7  106 keratinocytes
in 18 mL DMEM supplemented with 50 mg/mL ascorbic acid were
seeded on top (3 mL per well). Then 15 days later, SEs were grafted
onto the dorsal region of immunodeficient NMRI-Foxn1nu/Foxn1nu
nude mice (n = 18) using a skin flap procedure, as previously re-
ported.23,24 1 and 2 months later, mice were sacrificed and skin grafts
were taken for skin immunohistochemistry and molecular analysis.
To evaluate gene correction efficiency in grafted SE, 15 cryosections
of 5-mm thickness were subjected to genomic DNA extraction using
Genomic DNA from tissue kit (Macherey-Nagel). 50 ng genomicDNA of corresponding samples was subjected to ddPCR using
primers and probes complementary to the corrected or the mutated
sequence in exon 2 of COL7A1 (custom design), as already described
above.
The animal experiments were performed in compliance with guide-
lines for animal experiments in France and conducted in accordance
with the ethical principles.
Off-Target Site Analysis
Potential off-target sequences for gRNA N1 were identified by ZiFiT
Targeter 4.2 (http://zifit.partners.org) in the human genome. Only
3 potential off-targets (Off-Targets_1,2,3) were found with 2 MMs
in non-coding regions by ZiFiT Targeter 4.2. We also predicted off-
targets on http://crispr.mit.edu, and we identified 3 potential off-tar-
gets with 3 MMs (Off-Targets_4,5,6) and 2 potential off-targets with
4 MMs (Off-Targets_7,8) in coding regions. Overall, 8 off-target
sequences were subjected to the Surveyor cleavage assay. The genomic
DNA from RDEB-Ks treated with IDLVs encoding for the LV-
CRISPR-N1 (2 pg p24 per cell) and from genetically corrected
RDEB-Ks treated with IDLVs encoding for the LV-CRISPR-N1 and
the LV-Donor (2 pg p24/cell and 0.5 pg p24/cell) at 21 days post-
transduction was extracted, and the corresponding regions were
amplified by PCR using specific primers (Table S4). The Surveyor
cleavage assay was performed following the manufacturer’s instruc-
tions (Integrated DNA Technologies) at each potential off-target hit.
Transmission Electron Microscopy
For ultrastructural analysis, the central piece of each skin graft
(approximately 2 mm3) was dissected and immediately fixed with
Karnovsky’s fixative (2% formaldehyde and 4% glutaraldehyde in
cacodylate buffer). The ultrastructural analysis was performed at
the electron microscopy core facility in Cochin Institute, Paris.
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